A novel treatment (MA-5) developed by a Tohoku University-led research team will soon undergo phase II clinical trials at four medical institutions across Japan. MA-5 could provide hope for patients with mitochondrial diseases – as there are currently no approved treatments available.

For the first time, a new high-resolution microscopy technique has allowed researchers to watch live as influenza viruses infect cells. 

The international team led by ETH Zurich found that the cells actively promote virus uptake. 

This technique could now help to develop antiviral therapies in a more targeted manner. 

The multidrug-resistant pathogen Acinetobacter baumannii (A. baumannii) is a global health concern. Its surface capsular polysaccharides and lipopolysaccharides, which are structurally diverse and often contain rare, non-classical sugars, are major virulence factors. These glycans represent promising targets for novel therapeutics. Notably, glycoconjugate vaccines based on these structures elicit protective antibodies and confer effective immunity in animal models, highlighting their potential for combating infections.